237 related articles for article (PubMed ID: 25948551)
1. Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy.
Proia DA; Kaufmann GF
Cancer Immunol Res; 2015 Jun; 3(6):583-9. PubMed ID: 25948551
[TBL] [Abstract][Full Text] [Related]
2. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
Kumalo HM; Bhakat S; Soliman ME
Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
[TBL] [Abstract][Full Text] [Related]
3. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
4. HSP90 and Immune Modulation in Cancer.
Graner MW
Adv Cancer Res; 2016; 129():191-224. PubMed ID: 26916006
[TBL] [Abstract][Full Text] [Related]
5. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
Proia DA; Bates RC
Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
9. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
10. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
[TBL] [Abstract][Full Text] [Related]
11. Emerging Roles of Extracellular Hsp90 in Cancer.
Wong DS; Jay DG
Adv Cancer Res; 2016; 129():141-63. PubMed ID: 26916004
[TBL] [Abstract][Full Text] [Related]
12. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
15. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
16. Heat-Shock Protein 90-Targeted Nano Anticancer Therapy.
Rochani AK; Ravindran Girija A; Borah A; Maekawa T; Sakthi Kumar D
J Pharm Sci; 2016 Apr; 105(4):1454-66. PubMed ID: 26886301
[TBL] [Abstract][Full Text] [Related]
17. HSP90 inhibitors for cancer therapy and overcoming drug resistance.
Jhaveri K; Modi S
Adv Pharmacol; 2012; 65():471-517. PubMed ID: 22959035
[TBL] [Abstract][Full Text] [Related]
18. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
Moser C; Lang SA; Stoeltzing O
Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90 inhibitors as therapeutic agents.
Gomez-Monterrey I; Sala M; Musella S; Campiglia P
Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):313-36. PubMed ID: 22338602
[TBL] [Abstract][Full Text] [Related]
20. Heat shock proteins and cancer: How can nanomedicine be harnessed?
Sauvage F; Messaoudi S; Fattal E; Barratt G; Vergnaud-Gauduchon J
J Control Release; 2017 Feb; 248():133-143. PubMed ID: 28088573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]